Novartis Vaccines & Diagnostics, Gmbh

Novartis Ag

Chiron Corporation

University of Washington

3-V Biosciences, Inc.

Other

Achaogen, Inc.

Saginiet Biosciences Inc.

Sagimet Biosciences Inc.

Allan S Wagman

Keith Bruce Pfister

Simon C Ng

Savithri Ramurthy

Zhi-Jie Ni

Sharadha Subramanian

Marion Wiesmann

Robert S McDowell

John M Nuss

Stephen David Harrison

Marc Evanchik

Manoj C Desai

Weibo Wang

Kirk William Johnson

David B Ring

Sabina Pecchi

Paul Andrew Barsanti

Toni Beth Kline

Rustum S Boyce

Haiying Cai

Cristiana A Zaharia

Lily W Hu

Russell J Johnson

Lynn Seely

Niels H Andersen

Eric Harwood

Asha Yabannavar

Alice L Erwin

Jason Bowman

Khisimuzi E Mdluli

Ribhi Shawar

Paul A Renhowe

Martin Sendzik

Johan D Oslob

James Clifford Sutton

Matthew T Burger

Aaron Matthew Smith

Hanbiao Yang

Yanchen Zhang

Charles Voliva

Sarah Bartulis

Dane A Goff

Hong Yang

Daniel J Poon

Mark Knapp

Jiong Lan

Mika Lindvall

Wendy Fantl

Barry Haskell Levine

Teresa E Pick

Elizabeth J Mieuli

Victoria Sung

Anu Sharma

Joelle Verhagen

Gordana Babic Atallah

Xiaohui A Zhou

Gregory Duke

Johanna M Jansen

Alicia Louie

Edwin Iwanowicz

Thomas Hendrickson

Hanne Merritt

Liana M Klivansky

William Lenahan

Susan Kaufman

Sean P Brown

Douglas I Buckley

Kelly Frazier

Cynthia Shafer

Christopher McBride

Yasheen Zhou

Xiaodong Lin

Amy J Weiner

Heinz Ernst Moser

Timothy D Machajewski

Nicholas M Valiante

Rama Jain

Alice C Rico

Liana Marie Lagniton

Elisa Jazan

Robert L Warne

Payman Amiri

Carla C Heise

William R McCrea

Nathan Brammeier

Kelly Wayman

Timothy Sean Heuer

Mina E Aikawa

Jeffrey H Dove

Yamini Ohol-Gupta

Marie O'Farrell

Wei Shu

Dirksen Bussiere

Hanne Meritt

Xiahua Xin

Greg Duke

Xiaohua Xin

Xiaojong M Wang

Jeremy M Murray

Stephen E Basham

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

Heterocyclic modulators of lipid synthesis

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds.

Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. 

Pyrimidine derivatives used as PI-3 kinase inhibitors

Carbacephem &#x3b2;-lactam antibiotics having the following chemical structures (I) and (II) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar, R, Rand Rare as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistantspp.

Carbacephem &#x3b2;-lactam antibiotics

Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

CSF-1R inhibitors, compositions, and methods of use

Pyrimidine derivatives used as PI-3-kinase inhibitors

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.

PI 3-kinase inhibitors and methods of their use

Antibacterial compounds of formula I are provided:  As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Antibacterial agents

Growing community of inventors

Belmont, CA, United States of America

Allan S Wagman